#Mexico #Mexico City #Financial Growth #Genomma Lab #Banamex

Genomma Lab Internacional Secures Long-Term Debt

Genomma Lab Internacional, S.A.B. de C.V. (trading as LABB on the Mexican Stock Exchange), has secured a significant long-term credit facility amounting to MXN $1.0 billion from Banamex. This new financial agreement has a duration of three years and is part of Genomma Lab’s ongoing efforts to optimize its financial commitments.

This funding is intended primarily for refinancing and prepaying existing financial liabilities, which includes the repayment of an existing bank loan and the upcoming maturities of the company’s outstanding certificates. The strategic move is vital for the company as it seeks to strengthen its balance sheet while maintaining robust growth in the highly competitive pharmaceutical and personal care sectors.

Antonio Zamora Galland, Chief Financial Officer of Genomma Lab, expressed gratitude towards Banamex for their support, underlining that this long-term financing aligns with Genomma Lab’s strategy to enhance its debt maturity profile and fortify its working capital structure. He emphasized the importance of a solid financial position for sustaining growth and innovation in the product pipeline.

Jorge Rohana de la Vega, Corporate Director at Banamex, remarked on the commitment of Banamex to support local businesses like Genomma Lab. He highlighted that this credit facility exemplifies their dedication to the development of Mexican enterprises across various sectors, contributing positively to the economic landscape of Mexico.

Genomma Lab Internacional stands among the leading companies in the Latin American region, known for its rapid growth in both pharmaceutical and personal care markets. The company boasts a diverse portfolio of premium branded products that are market leaders in their categories. Their success can be attributed to a unique blend of innovative product development, consumer-focused marketing, extensive retail distribution, and a flexible supply chain model that minimizes costs while maximizing efficiency.

In light of recent global challenges, particularly the disruptions caused by the COVID-19 pandemic, enhancing their financial position is more important than ever for Genomma Lab. The continued uncertainties regarding economic stability and supply chain integrity necessitate proactive financial strategies. According to the company’s latest reports, it has taken measures to ensure consistent operations despite external pressures, and this new credit facility is a testament to their resilience and strategic foresight.

Forward-looking statements regarding the company’s future performance have been made, noting the potential risks and uncertainties that could influence actual outcomes, including market fluctuations and competition. The management urges stakeholders and investors to consider these factors when assessing Genomma Lab’s projected growth trajectory.

As they continue to evaluate new opportunities and challenges ahead, Genomma Lab remains optimistic about its future prospects supported by strong financial backing, innovative product offerings, and a commitment to operational excellence.

This latest financial maneuver is part of a broader effort to ensure that Genomma Lab is well-positioned to navigate the complexities of the market, meet consumer demands, and sustain its impressive growth across multiple channels in the upcoming years.